Literature DB >> 12784746

In-hospital clinical outcome in elderly patients with acute myocardial infarction treated with primary angioplasty.

Maurizio Tespili1, Giulio Guagliumi, Orazio Valsecchi, Giuseppe Musumeci, Angelina Vassileva, Antonio Saino, Pier Mario Scuri, Antonello Gavazzi.   

Abstract

BACKGROUND: The aim of the present study was to assess the early clinical outcome following primary coronary angioplasty in elderly patients (aged > or = 75 years) compared to younger patients (< 75 years).
METHODS: The study population included 655 consecutive patients (mean age 61.5 +/- 12.4 years) with acute ST-elevation myocardial infarction (MI) who underwent primary percutaneous coronary intervention (PCI) within 12 hours of symptom onset. Elderly patients accounted for 14.5% (96 of 655) of all patients. Primary PCI was performed using a balloon and/or coronary stent as well as glycoprotein IIb/IIIa inhibitors. The primary endpoint was the in-hospital incidence of major adverse cardiac events (including death, stroke, reinfarction, target vessel revascularization and new onset of heart failure).
RESULTS: Elderly patients were more frequently female (48 vs 20%, p < 0.001) and had more comorbid disease (prior stroke 7.2 vs 2.5%, p < 0.05) and more extensive cardiovascular disease (previous acute MI 13.5 vs 5.5%, p < 0.05; multivessel disease 71.8 vs 44.6%, p < 0.0005) and a significantly lower ejection fraction (48 vs 50%, p < 0.05). Despite a similar rate of TIMI 0-1 flow at presentation (69 vs 74%, p = NS), a similar use of stents (84 vs 86%, p = 0.3) and of glycoprotein IIb/IIIa inhibitor infusion (19.8 vs 22.1%, p = 0.3) and a comparable angiographic residual stenosis (21 vs 19%, p = NS), the final rate of TIMI 3 flow was significantly lower in the elderly population (77.8 vs 91.4%, p < 0.001). Although the in-hospital ischemic event rates for all ages were not significantly different, the in-hospital mortality was higher in the elderly as compared with younger patients (9.3 vs 3.2%, p < 0.0001), even when the patients with cardiogenic shock at the time of admission were excluded (4.4 vs 0.9%, p < 0.0001). Furthermore, more patients aged > or = 75 had in-hospital heart failure (5.2 vs 1.8%, p < 0.05). In the whole population, multivariate analysis identified baseline Killip class III-IV as the only independent predictor of events. In elderly patients, multivariate analysis identified baseline Killip class III-IV and the time from the onset of chest pain to PCI as independent predictors of events.
CONCLUSIONS: Our data suggest that in elderly patients with acute ST-elevation MI primary PCI yields positive results: successful reperfusion can be achieved in a high proportion of elderly patients and the mortality rates are lower, than those reported in non-PCI registries. A high Killip class and late reperfusion therapy predict an unfavorable outcome in elderly patients treated with primary PCI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12784746

Source DB:  PubMed          Journal:  Ital Heart J        ISSN: 1129-471X


  3 in total

1.  Intra-arterial recanalization techniques for patients 80 years or older with acute ischemic stroke: pooled analysis from 4 prospective studies.

Authors:  A I Qureshi; M F K Suri; A L Georgiadis; G Vazquez; N A Janjua
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-02       Impact factor: 3.825

2.  Myocardial infarction in patients over 90 years of age.

Authors:  Josef Yayan
Journal:  Clin Interv Aging       Date:  2012-02-28       Impact factor: 4.458

3.  Clinical impact of non-high density lipoprotein-cholesterol and apolipoprotein B on clinical outcomes in metabolic syndrome patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Khurshid Ahmed; Myung Ho Jeong; Rabin Chakraborty; Young Joon Hong; Mi Sook Oh; Kyung Hoon Cho; Min Chol Kim; Daisuke Hachinohe; Seung Hwan Hwang; Min Goo Lee; Doo Sun Sim; Keun Ho Park; Ju Han Kim; Youngkeun Ahn; Jung Chaee Kang
Journal:  Korean Circ J       Date:  2012-05-24       Impact factor: 3.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.